Improved Survival with Bevacizumab in Advanced Cervical Cancer

BACKGROUND: Vascular endothelial growth factor (VEGF) promotes angiogenesis, a mediator of disease progression in cervical cancer. Bevacizumab, a humanized anti-VEGF monoclonal antibody, has single-agent activity in previously treated, recurrent disease. Most patients in whom recurrent cervical canc...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Tewari, Krishnansu S., Sill, Michael W., Long, Harry J., Penson, Richard T., Huang, Helen, Ramondetta, Lois M., Landrum, Lisa M., Oaknin, Ana, Reid, Thomas J., Leitao, Mario M., Michael, Helen E., Monk, Bradley J.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2014
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4010094/
https://ncbi.nlm.nih.gov/pubmed/24552320
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1309748
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller